Temozolomide with or without WSD0922-FU for EGFR-mutant, IDH-wildtype glioblastoma
Original title: Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial that compares a new drug added to the usual treatment.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether adding a drug called WSD0922-FU to temozolomide helps slow this brain tumor down.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that is EGFR-mutant and IDH-wildtype. Those are features of the tumor itself. Some people get temozolomide alone. Others get temozolomide plus a drug called WSD0922-FU, which blocks EGFR and can reach the brain and spinal cord.
Where it stands. The trial is looking at whether adding WSD0922-FU slows the tumor from getting worse, compared to temozolomide by itself. The trial has not reported results. There is no answer yet.
What this means, and what it doesn't
What it could mean: This is one way researchers are trying to improve the usual treatment for this kind of glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. If your tumor has been tested and has these features, you could ask your care team whether a trial like this makes sense for you. They know your situation and can tell you what your options are.
What it doesn't mean: This does not mean WSD0922-FU works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that you will be helped, and some people in a trial get the usual treatment alone. This is not a promise of a cure. It also does not mean a spot is available to you. Only the trial team can decide who can join.
Source: ClinicalTrials.gov, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.